Nucleic Acid Delivery
Research Area: Novel biomaterials
RNAMEDs is developing clinically relevant delivery system based on novel biomaterials to facilitate effective RNA-based therapies, including degradable polymers, modified cyclodextrins, and lipid-like materials.
| Investigators |
Key Papers |
| Cyclodextrin-siRNA conjugates as versatile gene silencing agents. |
Research Area: New RNA cargo
We are utilising various types of RNA cargos for specific and durable control of protein expression in target cells such as short interfering RNA (siRNA), messenger RNA (mRNA), circularRNA (circRNA)
Research Area: Therapeutic areas
We are exploring the breakthrough therapeutic potential of RNA molecules for preventing multiple organ failure during sepsis, treatment of cancer (solid tumours and blood cancers), cardiovascular, neurodegenerative and inflammatory bowel diseases.
| Investigator |
Key Papers |
| Optimization of mRNA-Based delivery system for Anti-Her2 antibody expression in vivo |
Research Area: Oral delivery
We are addressing challenges for clinical translation for RNA therapeutic administration via non-invasive routes, such as oral delivery.
| Investigator |
Key Papers |
| Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this? |
Platform capabilities:
- Synthesis and characterization of polymeric and lipid-like biomaterials
- Design, formulation and characterization of non-viral systems for nucleic acids delivery
- Microfluidic based formulation of nanoparticles
- Processing; Freeze/Thaw, Lyophilisation
- Design, synthesis, and characterization of therapeutic RNAs
- Bio-predictive in-vitro and in-vivo testing of siRNA/mRNA formulations
- Pharmacological evaluation of the safety and efficacy of RNA therapeutics in disease relevant animal models (e.g.)